166 related articles for article (PubMed ID: 12775015)
1. Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey.
Kawai H; Ohtsu A; Boku N; Hamamoto Y; Nagashima F; Muto M; Sano Y; Mera K; Yano T; Doi T; Yoshida S
Gastric Cancer; 2003; 6 Suppl 1():19-23. PubMed ID: 12775015
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer.
Baba H; Yamamoto M; Endo K; Ikeda Y; Toh Y; Kohnoe S; Okamura T
Gastric Cancer; 2003; 6 Suppl 1():45-9. PubMed ID: 12775020
[TBL] [Abstract][Full Text] [Related]
3. Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer.
Nagashima F; Ohtsu A; Yoshida S; Ito K
Gastric Cancer; 2005; 8(1):6-11. PubMed ID: 15747168
[TBL] [Abstract][Full Text] [Related]
4. Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination.
Osugi H; Takada N; Takemura M; Kaseno S; Lee S; Ueno M; Tanaka Y; Fukuhara K; Fujiwara Y; Kinoshita H
Oncol Rep; 2002; 9(4):811-5. PubMed ID: 12066214
[TBL] [Abstract][Full Text] [Related]
5. Longterm control of advanced and recurrent gastric cancer (ARGC) by S-1.
Cho H; Konishi K; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Imada T
Gastric Cancer; 2003; 6 Suppl 1():24-7. PubMed ID: 12775016
[TBL] [Abstract][Full Text] [Related]
6. S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects.
Takahashi I; Kakeji Y; Emi Y; Sakurai M; Yonemura Y; Kimura Y; Maehara Y
Gastric Cancer; 2003; 6 Suppl 1():28-33. PubMed ID: 12775017
[TBL] [Abstract][Full Text] [Related]
7. Feasibility study of S-1 for resectable gastric cancer with peritoneal seeding.
Fujitani K; Tsujinaka T; Hirao M
Hepatogastroenterology; 2003; 50(51):889-92. PubMed ID: 12828112
[TBL] [Abstract][Full Text] [Related]
8. [Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer].
Ohtsu A
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():52-6. PubMed ID: 16897972
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
[TBL] [Abstract][Full Text] [Related]
10. Pilot study of S-1 in patients with disseminated gastric cancer.
Kitamura Y; Hayashi K; Sasagawa T; Oguma H; Takasaki K
Drugs Exp Clin Res; 2003; 29(3):125-30. PubMed ID: 14708458
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer.
Tsujitani S; Fukuda K; Kaibara N
Gastric Cancer; 2003; 6 Suppl 1():50-7. PubMed ID: 12775021
[TBL] [Abstract][Full Text] [Related]
12. [A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital].
Abe S; Kojima M; Tamura H; Kurihara H; Kitago M; Kobayashi T; Nakamura T; Ogihara T
Gan To Kagaku Ryoho; 2003 Jul; 30(7):963-70. PubMed ID: 12894711
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer.
Ishizone S; Maruta F; Saito H; Koide N; Sugiyama A; Nakayama J; Miyagawa S
Chemotherapy; 2006; 52(6):301-7. PubMed ID: 17008790
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of S-1 in patients with metastatic breast cancer--a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group.
Saek T; Takashima S; Sano M; Horikoshi N; Miura S; Shimizu S; Morimoto K; Kimura M; Aoyama H; Ota J; Noguchi S; Taguchi T
Breast Cancer; 2004; 11(2):194-202. PubMed ID: 15550867
[TBL] [Abstract][Full Text] [Related]
15. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
[TBL] [Abstract][Full Text] [Related]
16. Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer.
Yamanaka T; Matsumoto S; Teramukai S; Ishiwata R; Nagai Y; Fukushima M
Gastric Cancer; 2007; 10(2):129-34. PubMed ID: 17577624
[TBL] [Abstract][Full Text] [Related]
17. [The clinical effect of TS-1 in advanced and recurrent gastric cancer with peritoneal dissemination].
Inaba Y; Watabe S; Ohe S; Kamio Y; Koyama M; Hayashi K; Chiba M
Gan To Kagaku Ryoho; 2002 Feb; 29(2):239-44. PubMed ID: 11865630
[TBL] [Abstract][Full Text] [Related]
18. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
[TBL] [Abstract][Full Text] [Related]
19. [An investigation of TS-1 single-agent therapy administered as first-line therapy for unresectable advanced gastric cancer].
Nukaya H; Hirashima N; Tanaka Y; Endo M; Matsunaga S; Hasegawa I; Kato A; Sakakibara K; Sakamoto T; Kondo H
Gan To Kagaku Ryoho; 2005 Oct; 32(10):1421-6. PubMed ID: 16227741
[TBL] [Abstract][Full Text] [Related]
20. [A case of liver metastasis of gastric cancer responding well to TS-1].
Niinobu T; Yamamoto M; Taniguchi M; Kotobuki T; Otsuka A
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1674-7. PubMed ID: 15553680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
